Revenue reached $37.0 million in 2025 with a 63% gross margin, driven by growth in biologics, navigation, laser therapy, and neurocritical care. The company targets $200m annual revenue from existing markets and $300m from new cell and gene therapy markets, supported by 60+ pharma partners and rece…
Revenue reached $37.0 million in 2025 with a 63% gross margin, driven by growth in biologics, navigation, laser therapy, and neurocritical care. The company targets $200m annual revenue from existing markets and $300m from new cell and gene therapy markets, supported by 60+ pharma partners and recent FDA approvals.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
